Biotechnology & Pharmaceuticals in Singapore

Comprehensive modality portfolio

Singapore is home to over 60 biopharmaceutical manufacturing sites across diverse modalities – spanning small-molecule Active Pharmaceutical Ingredients (APIs), biologics, and new emerging modalities like cell and gene therapies and Antibody-Drug Conjugates (ADCs).

Establishing best-in-class facilities

Companies have the opportunity to establish best-in-class facilities within their global networks, leveraging Singapore's strong connectivity, skilled talent pool, and regulatory excellence as a gateway into Asia-Pacific.

Sustainability as a differentiator

Singapore offers a platform for companies to explore and implement sustainability initiatives – including zero carbon plants and renewable energy-powered facilities – helping them meet global sustainability targets while unlocking longer-term cost savings.

Flexible R&D models

Whether it is pursuing in-house R&D like Chugai, or open innovation partnerships like J&J and Sanofi, companies can leverage Singapore's ecosystem to execute their R&D strategy in a way that best aligns with their innovation goals.

Digital and AI capabilities

Singapore's National AI Strategy will triple the local AI talent pool to 15,000 and invest S$120 million in "AI for Science", accelerating the development and adoption of AI methods and tools in domains such as biomedical and health sciences.

Companies like Eli Lilly and MSD have anchored AI and digital hubs here, contributing to a growing ecosystem in Singapore and fostering the next generation of biopharmaceutical breakthroughs.

Strong venture and corporate support

Singapore's biotech ecosystem is supported by significant venture capital investments with the likes of Novo Holdings and Polaris Partners actively investing in local biotech ventures. Flagship Pioneering's partnership with A*STAR to jointly commit S$100 million will also promote collaborations and drive innovation within the biotech ecosystem in Singapore.